

REMARKS

The specification has been amended at pages 15 and 18 to correct typographical errors in the name of a chemical reactant. These errors are obvious from the context of the specification, in view of the cited reference *J. Med. Chem.* **1991**, 34, 656, and are likewise apparent from the products prepared therefrom in which no benzyl groups are present.

The specification has also been amended on page 17 to correct a typographical error in which a solvent was listed incorrectly as dichloromethanol instead of dichloromethane. This is an obvious error in view of the disclosure at page 9, lines 8-10, in which it is stated that the dehydration reaction is “preferably carried out with phosphorous oxychloride in dichloromethane.”

Claims 1-29 have been cancelled and new claims 30-74 have been added in order to write the original claims in appropriate U.S. claim format and to limit the multiple dependencies of these claims.

Support for claims 30-43 occurs, for example, in original claims 1-7, and on page 2 of the specification.

Support for claims 44-48 occurs, for example, in original claims 8-12.

Support for claim 49 occurs, for example, in original claims 13-18.

Support for claims 50-58 occurs, for example, in original multiple dependent claim 19, and on page 13, lines 14-17 of the specification.

Support for claim 59 occurs, for example, in original claim 20.

Support for claims 68-74 can be found, for example, in original claims 23-28.


Use claim 21 is cancelled and replaced by new U.S. appropriate method-of-use claims 60-63 written in singly dependent form.

Use claim 22 is cancelled and replaced by new U.S. appropriate method-of-use claims 64-67 written in singly dependent form.

Claims 30-74 are in the application as amended.

Respectfully submitted,

Date: September 7, 2004



Michael D. Alexander
Reg. No. 36,080

Address
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No. (610) 889-6338
Facsimile: (610) 889-8799